The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Merck emphasized the broader significance of the findings
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
